Preemptive Action: Reducing the Risk of Breast Cancer

Elena Beyzarov, PharmD
Published Online: Thursday, June 14, 2012
Follow Pharmacy_Times:
Pharmacy Times Office of Continuing Professional Education


Preemptive Action: Reducing the Risk of Breast Cancer

Elena Beyzarov, PharmD

Scientific Director Pharmacy Times Office of Continuing Professional Education

Elena Beyzarov, PharmD, has no relevant affiliations or financial relationships with commercial interests to disclose related to this activity

Pharmacy Times Office of Continuing Professional Education Planning Staff

Judy V. Lum, MPA, and Ann C. Lichti, CCMEP have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.

Pharmacy Times Editorial

Bea Riemschneider, Jennifer Barrio, and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity


Educational Objectives

Upon completion of this educational activity, participants should be able to:
  1. Describe the current incidence and prevalence of breast cancer among American women.
  2. Examine factors associated with increased risk of breast cancer, including lifestyle, genetic factors, and hormone replacement therapy.
  3. Examine factors associated with decreased risk of breast cancer, focusing on chemoprevention strategies.
  4. Discuss implications for pharmacists in regard to addressing common patient questions on breast cancer risks and providing evidence-based information on chemoprevention and use of dietary supplements.

Target Audience: Pharmacists

Type of Activity: Knowledge

Release date: June 10, 2012

Expiration date: June 10, 2014

Estimated time to complete activity: 2 hours

Fee: This lesson is free online at www.PharmacyTimes.com. There is a nominal fee of $10.00 for mailed/faxed evaluation and exam forms.

Click here to view this activity



Related Articles
The FDA has granted priority review status to Amgen’s supplemental New Drug Application for its carfilzomib (Kyprolis) cancer therapy.
Teikoku Pharma USA has submitted a New Drug Application to the FDA for the product.
Cancer drug prices have increased 10% each year since 1995, even after adjusting for inflation and incremental health benefits.
Cyramza, manufactured by Eli Lilly and Company, is an angiogenesis inhibitor indicated for the treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with disease progression on or after treatment with prior fluoropyrimidine- or platinum-containing chemotherapy.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$